Clinical Significance of Serum IL-12 Level in Patients with Early Breast Carcinoma and Its Correlation with Other Tumor Markers

Samar Samir Youssef; Manal Moussa Mohammad; Lobna R. Ezz-El-Arab

doi:10.3889/oamjms.2015.106

Authors

Samar Samir Youssef National Research Center, Microbial Biotechnology Department, Cairo
Manal Moussa Mohammad National Research Center, Medical Physiology Department, Medical Research Division, Cairo 11331
Lobna R. Ezz-El-Arab Faculty of Medicine, Ain Shams University, Radiation Oncology and Nuclear Medicine, Cairo

DOI:

https://doi.org/10.3889/oamjms.2015.106

Keywords:

Breast cancer, hormone receptor, prognosis, tumor markers, IL-12

Abstract

AIM: To investigate the diagnostic significance of Interleukin 12 (IL-12) in breast cancer (BC) and its correlation with other tumor markers including cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinases-1 (TIMP-1), and MMP9/TIMP1 ratio.

METHODS: Serum levels of IL-12, tumor markers, and hormone receptors were measured in 92 BC and 56 benign lesion patients versus 40 healthy subjects. Clinical stage, tumor size, lymph node metastasis, grade, and histological type were recorded.

RESULTS: BC patients have lower IL-12, but higher CA 15.3 and CEA than control group. High levels of serum IL-12 were associated with lymph node positivity and progesterone receptor negativity. IL-12 was significant lower in invasive ductal carcinoma (IDC) compared to non IDC histological type. IL-12 was higher in patients with higher stage and grade but the difference was not statistically significant.IL-12 correlates negatively with MMP9/TIMP1 ratio.

CONCLUSION: IL-12 is less specific than CEA for screening early BC, but its correlation with tumor aggressiveness and progression markers may have a prognostic value.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Allemani C, Sant M, Weir HK, et al. breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer. 2013;132:1170â€“1181.

http://dx.doi.org/10.1002/ijc.27725 DOI: https://doi.org/10.1002/ijc.27725

PMid:22815141

Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer. 2010;127(12):2893-917.

http://dx.doi.org/10.1002/ijc.25516 DOI: https://doi.org/10.1002/ijc.25516

PMid:21351269

Rao V S, Dyer C E, Jameel JK, et al. Potential prognostic and therapeutic roles for cytokines in breast cancer. Oncol Rep. 2006;15(1):179â€“185.

http://dx.doi.org/10.3892/or.15.1.179 DOI: https://doi.org/10.3892/or.15.1.179

Yao-Lung K, Dar-Ren C, and Tsai-Wang C. Clinicopathological features of triple-negative breast cancer in Taiwanese women. Int J Clin Oncol. 2011;16(5):500â€“505.

http://dx.doi.org/10.1007/s10147-011-0211-9 DOI: https://doi.org/10.1007/s10147-011-0211-9

PMid:21455625

Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122(9):2050-6.

http://dx.doi.org/10.1002/ijc.23337 DOI: https://doi.org/10.1002/ijc.23337

PMid:18172859

Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22.

http://dx.doi.org/10.1038/nrc1252 DOI: https://doi.org/10.1038/nrc1252

PMid:14708024

Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003;5: 31-36.

http://dx.doi.org/10.1186/bcr554 DOI: https://doi.org/10.1186/bcr554

PMid:12559043 PMCid:PMC154133

Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigenspecific adaptive immunity. Annu Rev Immunol. 1995;13:251â€“76.

http://dx.doi.org/10.1146/annurev.iy.13.040195.001343 DOI: https://doi.org/10.1146/annurev.iy.13.040195.001343

PMid:7612223

Merendino RA, et al. Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett. 1999;68:355â€“358.

http://dx.doi.org/10.1016/S0165-2478(99)00067-X DOI: https://doi.org/10.1016/S0165-2478(99)00067-X

Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995; 87: 581â€“586.

http://dx.doi.org/10.1093/jnci/87.8.581 DOI: https://doi.org/10.1093/jnci/87.8.581

PMid:7538593

Teicher BA, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer. 1994; 57: 1â€“6.

http://dx.doi.org/10.1002/ijc.2910570624 DOI: https://doi.org/10.1002/ijc.2910570624

Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer. 1998;78(3):361-5.

http://dx.doi.org/10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9 DOI: https://doi.org/10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9

Hussein MZ, Al Fikky A, Abdel Bar I, et al. Serum IL-6 and IL-12 levels in breast cancer patients. Egypt J Immunol. 2004;11(2):165-70.

PMid:16734129

Derin D, Soydinc HO, Guney N, Tas F, et al. Serum IL-8 and IL-12 levels in breast cancer. Med Oncol. 2007;24(2):163-8.

http://dx.doi.org/10.1007/BF02698035 DOI: https://doi.org/10.1007/BF02698035

PMid:17848739

Rao V S, Alabi A, Dyer C E, et al. IL-10 and IL-12 expression in breast cancer patients and effect of therapy. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008; 26(15S):14016. DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.14016

Colombo MP, Trinchieri G. Interleukin-12 in anti- tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155-68.

http://dx.doi.org/10.1016/S1359-6101(01)00032-6 DOI: https://doi.org/10.1016/S1359-6101(01)00032-6

Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957, 11:359-377.

http://dx.doi.org/10.1038/bjc.1957.43 DOI: https://doi.org/10.1038/bjc.1957.43

PMid:13499785 PMCid:PMC2073885

Sobin LH, Wittekind C. International Union against Cancer (UICC). (2002) TNM classification of malignant tumors. 6th ed. New York (NY): Wiley-Liss, 2002.

Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007;9(1):R15.

http://dx.doi.org/10.1186/bcr1648 DOI: https://doi.org/10.1186/bcr1648

PMid:17261184 PMCid:PMC1851386

Smyth MJ, Cretney E, Kershaw MH, et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2004;202:275-293.

http://dx.doi.org/10.1111/j.0105-2896.2004.00199.x DOI: https://doi.org/10.1111/j.0105-2896.2004.00199.x

PMid:15546400

Brunda, MJ, Luistro, L, Warrier, RR, et al. Anti tumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223â€“1230.

http://dx.doi.org/10.1084/jem.178.4.1223 DOI: https://doi.org/10.1084/jem.178.4.1223

PMid:8104230

Boggio, K, Nicoletti, G, Di Carlo, E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med. 1998;188:589â€“596.

http://dx.doi.org/10.1084/jem.188.3.589 DOI: https://doi.org/10.1084/jem.188.3.589

PMid:9687535 PMCid:PMC2212479

Del Vecchio M, Bajetta, E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007;13:4677â€“4685.

http://dx.doi.org/10.1158/1078-0432.CCR-07-0776 DOI: https://doi.org/10.1158/1078-0432.CCR-07-0776

PMid:17699845

Lissoni P1, Mengo S, MandalÃ M, et al. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy. J Biol Regul Homeost Agents. 1998;12(1-2):38-41.

PMid:9677534

Freund A, Chauveau C, Brouillet JP, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene. 2003;22:256-265.

http://dx.doi.org/10.1038/sj.onc.1206113 DOI: https://doi.org/10.1038/sj.onc.1206113

PMid:12527894 PMCid:PMC2034407

Galien R, Garcia T: Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 1997;25:2424-2429.

http://dx.doi.org/10.1093/nar/25.12.2424 DOI: https://doi.org/10.1093/nar/25.12.2424

Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90-119.

http://dx.doi.org/10.1210/edrv.23.1.0456 DOI: https://doi.org/10.1210/edrv.23.1.0456

PMid:11844745

Salem ML. Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy. 2004; 3:97-104.

http://dx.doi.org/10.2174/1568010043483944 DOI: https://doi.org/10.2174/1568010043483944

PMid:15032646

Davies S, Dai D, Wolf DM, et al. Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells. J Soc Gynecol Investig. 2004;11:494-499.

http://dx.doi.org/10.1016/j.jsgi.2004.04.003 DOI: https://doi.org/10.1016/j.jsgi.2004.04.003

PMid:15458748

Kanda N, Watanabe S. 17Beta-estradiol inhibits MCP-1 production in human keratinocytes. J Invest Dermatol. 2003; 120:1058-1066.

http://dx.doi.org/10.1046/j.1523-1747.2003.12255.x DOI: https://doi.org/10.1046/j.1523-1747.2003.12255.x

Loudon JA, Elliott CL, Hills F, et al. Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol Reprod. 2003; 69:331-337.

http://dx.doi.org/10.1095/biolreprod.102.013698 DOI: https://doi.org/10.1095/biolreprod.102.013698

PMid:12672669

Kelly RW, Carr GG, Riley SC: The inhibition of synthesis of a beta-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochem Biophys Res Commun. 1997;239:557-561.

http://dx.doi.org/10.1006/bbrc.1997.7502 DOI: https://doi.org/10.1006/bbrc.1997.7502

PMid:9344869

Carpi A, Nicolini A, Antonelli A, et al. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Targets. 2009; 9(8):888-903.

http://dx.doi.org/10.2174/156800909790192392 DOI: https://doi.org/10.2174/156800909790192392

PMid:20025599

Schrohl, A, Christensen, IJ, Pedersen, AN, et al. tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) andplasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics. 2003;2(3):164âˆ’172.

http://dx.doi.org/10.1074/mcp.M300019-MCP200 DOI: https://doi.org/10.1074/mcp.M300019-MCP200

PMid:12672830

Wurtz, SO, Christensen, I.J, Schrohl, AS, et al. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics. 2005;4(4): 483âˆ’491.

http://dx.doi.org/10.1074/mcp.M400209-MCP200 DOI: https://doi.org/10.1074/mcp.M400209-MCP200

PMid:15640527